Schild OBE - Integrated Biopharma Chief iBioPharma
| INBPDelisted Stock | USD 0.33 0.00 0.00% |
Insider
Schild OBE is Chief iBioPharma of Integrated Biopharma
| Age | 85 |
| Phone | 888 319 6962 |
| Web | https://www.ibiopharma.com |
Integrated Biopharma Management Efficiency
The company has return on total asset (ROA) of 0.0336 % which means that it generated a profit of $0.0336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Integrated Biopharma's management efficiency ratios could be used to measure how well Integrated Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Integrated Biopharma currently holds 53 K in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Integrated Biopharma has a current ratio of 3.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Integrated Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Integrated Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Integrated Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Integrated to invest in growth at high rates of return. When we think about Integrated Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Kenneth Tuchman | Treehouse Foods | 69 | |
| Marcus Opitz | Aryzta AG PK | 62 | |
| Amit Philip | Treehouse Foods | 46 | |
| Yilmaz Erceyes | Premier Foods Plc | N/A | |
| Tomohide Hayama | Toyo Suisan Kaisha | 57 | |
| Shigeru Komuro | Calbee Inc | N/A | |
| Ronan Minahan | Aryzta AG PK | N/A | |
| Kazuya Tasaki | Calbee Inc | N/A | |
| Richard Martin | Premier Foods Plc | N/A | |
| Jason Tyler | Treehouse Foods | 50 | |
| Duncan Leggett | Premier Foods Plc | N/A | |
| Mark Hunter | Treehouse Foods | 57 | |
| Urs Jordi | Aryzta AG PK | 58 | |
| Armin Bieri | Aryzta AG PK | 59 | |
| Scott Ostfeld | Treehouse Foods | 43 | |
| Paul Thompson | Premier Foods Plc | N/A | |
| Kristy Waterman | Treehouse Foods | 43 | |
| Brady Millerberg | Aryzta AG PK | N/A | |
| John Gainor | Treehouse Foods | 64 | |
| Alexander Whitehouse | Premier Foods Plc | N/A | |
| Martin Huber | Aryzta AG PK | 53 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0336 |
Integrated Biopharma Leadership Team
Elected by the shareholders, the Integrated Biopharma's board of directors comprises two types of representatives: Integrated Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integrated. The board's role is to monitor Integrated Biopharma's management team and ensure that shareholders' interests are well served. Integrated Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integrated Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Schild OBE, Chief iBioPharma | ||
| Dina Masi, CFO, Sr. VP and Secretary | ||
| Nickolas Palin, Pres Segment | ||
| Robert Erwin, Pres iBioPharma | ||
| Riva Sheppard, Executive Vice President Director | ||
| Gerald Kay, Chairman, CEO and Pres | ||
| Jamie Levey, Head Relations | ||
| Christina Kay, Executive VP and Director | ||
| Orn Adalsteinsson, Chief Inc |
Integrated Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Integrated Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0336 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 12.05 M | ||||
| Shares Outstanding | 29.95 M | ||||
| Shares Owned By Insiders | 68.58 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Price To Earning | 2.52 X | ||||
| Price To Book | 0.56 X |
Pair Trading with Integrated Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integrated Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrated Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Integrated OTC Stock
| 0.54 | PPC | Pilgrims Pride Corp | PairCorr |
| 0.5 | BRCNF | Burcon NutraScience Corp | PairCorr |
| 0.46 | FRPT | Freshpet Potential Growth | PairCorr |
| 0.44 | LW | Lamb Weston Holdings | PairCorr |
| 0.37 | DAR | Darling Ingredients | PairCorr |
The ability to find closely correlated positions to Integrated Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Integrated Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Integrated Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Integrated Biopharma to buy it.
The correlation of Integrated Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Integrated Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Integrated Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Integrated Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |